Niccolò Bolli Selected Research

Nucleophosmin

1/2011	Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
4/2010	Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish.
8/2008	A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1).
5/2008	Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.
7/2007	Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants.
4/2007	Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.
12/2006	Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification.
9/2006	Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.
6/2006	Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.
4/2006	Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Niccolò Bolli Research Topics

Disease

10	Neoplasms (Cancer) 12/2021 - 01/2004
8	Multiple Myeloma 07/2022 - 01/2020
8	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2011 - 06/2006
2	Hematologic Neoplasms (Hematological Malignancy) 11/2021 - 04/2007
2	Plasma Cell Leukemia 09/2021 - 12/2007
2	Residual Neoplasm 05/2008 - 04/2007
1	Autosomal Dominant Rhegmatogenous Retinal Detachment 07/2022
1	Chromothripsis 11/2021
1	Carcinogenesis 06/2021
1	Chromosome Aberrations (Chromosome Abnormalities) 01/2011
1	Syncope (Fainting) 12/2007
1	Multiple Abnormalities 12/2007
1	Ventricular Tachycardia 12/2007
1	Lymphoma (Lymphomas) 04/2007
1	Leukemia 04/2007
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 04/2007
1	Myeloid Sarcoma (Chloroma) 04/2006

Drug/Important Bio-Agent (IBA)

10	NucleophosminIBA 01/2011 - 04/2006
7	Biological ProductsIBA 12/2021 - 04/2007
2	Biomarkers (Surrogate Marker)IBA 12/2021 - 01/2021
2	ParaffinIBA 11/2021 - 09/2006
2	DNA (Deoxyribonucleic Acid)IBA 05/2020 - 08/2013
2	Proteins (Proteins, Gene)FDA Link 04/2007 - 04/2005
1	Melphalan (Alkeran)FDA LinkGeneric 07/2022
1	NucleotidesIBA 02/2022
1	Pharmaceutical PreparationsIBA 12/2021
1	Immunomodulating AgentsIBA 11/2021
1	Protein Isoforms (Isoforms)IBA 11/2021
1	Antisense OligonucleotidesIBA 11/2021
1	Formaldehyde (Formol)FDA Link 11/2021
1	venetoclaxIBA 09/2021
1	Mitochondrial DNA (mtDNA)IBA 06/2021
1	Circulating Tumor DNAIBA 08/2020
1	thiamine triphosphorate (TTP)IBA 01/2020
1	CytidineIBA 08/2013
1	PhosphoproteinsIBA 04/2010
1	Nuclear Proteins (Protein, Nuclear)IBA 05/2008
1	Thalidomide (Thalomid)FDA Link 12/2007
1	Nuclear Export Signals (Nuclear Export Signal)IBA 07/2007
1	AntibodiesIBA 04/2007
1	Anaplastic Lymphoma KinaseIBA 04/2007
1	Annexin A6IBA 04/2005
1	Monoclonal AntibodiesIBA 04/2005
1	polyacrylamideIBA 04/2005
1	Alemtuzumab (Campath)FDA Link 01/2004

Therapy/Procedure

2	Therapeutics 07/2022 - 08/2013
1	Immunotherapy 12/2021
1	Drug Therapy (Chemotherapy) 02/2015
1	Molecular Targeted Therapy 05/2008